Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1070336/000119312519067172/d678011d10k.htm
SEC Filings
1070336 Annual Reports
1070336 Quarterly Reports
1070336 Corporate News
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change January 2020
Earnings Release
Financial Exhibit
Other Events January 2020
Other Events January 2020
Other Events January 2020
Financial Exhibit
Other Events
Vote of Security Holders December 2019
Earnings Release
Financial Exhibit
Other Events November 2019
Bylaw Change
Financial Exhibit
New Agreement
Other Events October 2019
New Agreement
New Financial Obligation September 2019
Earnings Release
Financial Exhibit August 2019
Bylaw Change
Financial Exhibit
Vote of Security Holders June 2019
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
January 2020
Earnings Release
Financial Exhibit
Other Events
Financial Exhibit
Other Events
January 2020
Other Events
January 2020
Other Events
January 2020
Financial Exhibit
Other Events
Vote of Security Holders
Other Events
Vote of Security Holders
December 2019
Earnings Release
Financial Exhibit
Other Events
Financial Exhibit
Other Events
November 2019
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Financial Exhibit
New Agreement
Other Events
October 2019
New Agreement
New Financial Obligation
New Financial Obligation
September 2019
Earnings Release
Financial Exhibit
Financial Exhibit
August 2019
Bylaw Change
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
June 2019
Last10K.com | 10-K Annual Report Thu Mar 07 2019
Document And Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2018 | Mar. 01, 2019 | Jun. 29, 2018 | |
| Document Information [Line Items] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2018 | ||
| Document Fiscal Year Focus | 2018 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | ACHILLION PHARMACEUTICALS INC | ||
| Entity Central Index Key | 0001070336 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Public Float | $ 381,951,346 | ||
| Trading Symbol | ACHN | ||
| Entity Common Stock, Shares Outstanding | 138,715,675 | ||
| Entity Shell Company | false | ||
| Entity Emerging Growth Company | false | ||
| Entity Small Business | true |
View differences made from one year to another to evaluate Achillion Pharmaceuticals Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Achillion Pharmaceuticals Inc.
Assess how Achillion Pharmaceuticals Inc's management team is paid from their Annual Proxy
Achillion Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Revenue - Product Highlight
Under the new standard, we apply the following five-step model in order to determine the amount and timing of revenue to be recognized: (i) identification of the promised services in the contract; (ii) determination of whether the promised services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
-
Financial - Expense Highlight
Research and development expenses consisted of the following: The decrease in research and development expenses for the year ended December 31, 2018, as compared to the year ended December 31, 2017, was primarily due to decreased manufacturing and formulation costs related to ACH-5228 and decreased discovery research costs, combined with decreased personnel costs and non-cash stock compensation due to fewer employees, including fewer executives.
-
Financial - Expense Highlight
Our research and development expenses reflect costs incurred for our proprietary research and development projects which consist primarily of salaries and benefits for our research and development personnel, costs of services by clinical research organizations, other outsourced research, materials used during research and development activities, facility-related costs such as rent and utilities associated with our laboratory and clinical development space and operating supplies.
-
Financial - Expense Highlight
Our research and development expenses consist primarily of salaries and benefits for our research and development personnel, costs of services by clinical research organizations, other outsourced research, materials used during research and development activities, facility-related costs such as rent and utilities associated with our laboratories and clinical development space, operating supplies and other costs associated with our research and development activities.
-
Financial - Expense Highlight
General and administrative expenses consisted of the following: The decrease in general and administrative expenses for the year ended December 31, 2018, as compared to the year ended December 31, 2017, was primarily due to decreased corporate legal fees and consulting fees combined with our payment of $2.9 million in underwriting fees in connection with the sale by JJDC in November 2017 of all of the shares of our common stock it acquired pursuant to the JJDC Stock Purchase Agreement.
-
Financial - Expense
The increase in research and...Read more
-
Other - Other
Subsequently, in July of 2018,...Read more
-
Financial - Expense
These amounts were partially offset...Read more
-
Financial - Shares
Through December 31, 2018, we...Read more
-
Financial - Shares
Through December 31, 2018, we...Read more
-
Financial - Expense
We expect research and development...Read more
-
Other - Other
Pursuant to the terms of...Read more
-
Other - Other
We adopted the provisions of...Read more
-
Other - Other
The restructuring plan was implemented...Read more
-
Other - Other
On September 9, 2017, we...Read more
-
Other - Other
On September 9, 2017, we...Read more
-
Other - Other
The Janssen Agreement was terminated...Read more
-
Other - Other
In addition, we may seek...Read more
-
Financial - Debt
As of December 31, 2018,...Read more
-
Other - Other
If our operating plan changes,...Read more
-
Other - Other
ASU No. 2018-07 is effective...Read more
-
Other - Other
ASU No. 2016-02 is effective...Read more
-
Other - Other
ASU No. 2016-15 was effective...Read more
-
Other - Other
The guidance was effective for...Read more
-
Other - Other
The guidance was effective for...Read more
-
Other - Other
ASU No. 2017-09 was effective...Read more
-
Other - Other
All other amendments should be...Read more
-
Other - Other
ASU No. 2018-13 is effective...Read more
-
Revenue - Product
Further, in February 2017, we...Read more
-
Other - Other
Our financial statements reflect expected...Read more
-
Other - Other
There can be no assurance...Read more
-
Other - Other
The amendment provided for a...Read more
-
Other - Other
Any performance obligations under our...Read more
-
Other - Other
There can be no assurance...Read more
-
Other - Other
Such additional financing may not...Read more
-
Financial - Expense
We expect that research and...Read more
-
Other - Other
We believe that an overactive...Read more
-
Other - Other
We believe that an overactive...Read more
-
Revenue - Product
Prior to the adoption of...Read more
-
Financial - Debt
As of December 31, 2018,...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses (Detail)
Accrued Expenses And Other Long-Term Liabilities
Accrued Expenses And Other Long-Term Liabilities (Tables)
Assumptions Used To Value Options Granted (Detail)
Assumptions Used To Value Options Granted Under Two Thousand And Six Employee Stock Purchase Plan (Detail)
Calculations Of Basic And Diluted Net Loss Per Share (Detail)
Capital Structure
Capital Structure - Additional Information (Detail)
Collaboration Arrangements
Collaboration Arrangements - Additional Information (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Company's Stock Option Activity (Detail)
Compensation Expense Related To Option Grants Made To Employees And Consultants (Detail)
Earnings (Loss) Per Share
Earnings (Loss) Per Share (Tables)
Fair Value Of Investments (Detail)
Fixed Assets, Net
Fixed Assets, Net (Tables)
Fixed Assets, Net - Additional Information (Detail)
Future Minimum Annual Lease Payments (Detail)
Future Tax Benefits (Deferred Tax Assets) (Detail)
Income Tax Provision (Benefit) (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Marketable Securities
Marketable Securities (Tables)
Marketable Securities - Additional Information (Detail)
Nature Of Business - Additional Information (Detail)
Nature Of The Business
Net Operating Loss And Credit Carryforwards (Detail)
Potentially Dilutive Securities Outstanding (Detail)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Property And Equipment, Net Estimated Useful Lives (Detail)
Quarterly Financial Data (Detail)
Reconciliation Of Provision For Income Taxes At Statutory Rates (Detail)
Related Party Transactions
Related Party Transactions - Additional Information (Detail)
Restructuring Plan
Restructuring Plan - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Summary Of Contractual Maturities Of Investments (Detail)
Summary Of Investments (Detail)
Summary Of Prepaid Expenses And Other Current Assets (Detail)
Summary Of Property And Equipment (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Stock Options Outstanding (Detail)
Unaudited Quarterly Results
Unaudited Quarterly Results (Tables)
Material Contracts, Statements, Certifications & more
Achillion Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits
CIK: 1070336
Form Type: 10-K Annual Report
Accession Number: 0001193125-19-067172
Submitted to the SEC: Thu Mar 07 2019 11:03:49 AM EST
Accepted by the SEC: Thu Mar 07 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Bookmark the Permalink: https://last10k.com/sec-filings/1070336/0001193125-19-067172.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...